Clinical Trials
2 trialsNCT01702064 2021-01-05
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02225574 2020-02-12
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
M.D. Anderson Cancer Center
Phase 1 Terminated